INTRODUCTION 52
Condyloma acuminatum (CA) is a wide-spread sexually transmitted disease with 53 increasing prevalence during the past decades [1] . CA is caused by human 54 papillomavirus (HPV) infection. Infection with high-risk HPV strains is closely 55 associated cervical cancer as well as other type of cancer in the anogenital region [2, 56 3]. HPV16 is a major risk for the development of oropharyngeal 57 squamous-cell-carcinoma [4, 5] . HPV infection causes mental distresses and produces 58 negative impact on sexual life and social well-being of infected individuals. Clearance 59 of HPV virus is the goal for the treatment of genital warts and could prevent cancers. 60 Most of the currently available treatments focus on clearing the externally visible warts rather than targeting the viruses [6, 7 ]. An animal model for CA that look into 62 both the local and systemic immune responses is essential for development of new 63 treatments [8, 9] . 64 Host immune responses and chronic inflammation have been shown to be 65 important risk factors for HPV-related carcinogenesis [10] . Increased duration of HPV 66 infection could influence disease development, indicating the importance of the host 67 immune response to HPV clearance and HPV-related carcinogenesis. Immune 68 responses to invading HPV consist of innate and adaptive immune systems.
69
Langerhans cells are immature dendritic cell (mDC), and the only 70 professional antigen-presenting cells in the epidermis. [11, 12] 
76
As a result, koilocytes in CA may be associated with HPV infection.
77
Imiquimod is an immuno-modulating agent with actions at multiple levels of the 78 adaptive immune system. Imiquimod activates the cells of the immune system via toll 79 like receptor, and increase the secretion of cytokines, including TNF-α, IL-1β, and Female BALB/C-nu nude mice (4-6 weeks of age; Experimental Animal Center, the Hematology) were used in this study. The mice were housed in a specific-pathogen 105 free facility. (Figure 1h ). Mice receiving imiquimod group and interferon-α-2b group had 175 higher IL-2 levels than 1:20 PaiTeLing group (P<0.001, P<0.01, respectively), but 176 there was no statistical significance compared with the 1:2 PaiTeLing group ( Figure   177 1d). All four groups of mice receiving treatments had similar IL-12p70 levels ( Figure  1f ). In comparison with the 1:20 PaiTeLing group and the 1:2 PaiTeLing group, mice 179 receiving imiquimod (P<0.01, P<0.01, respectively) and mice receiving 180 interferon-α-2b (P<0.01, P<0.01, respectively) had lower IFN-γ levels (Figure 1b) . [35] [36] [37] and imiquimod [38, 39] in patients with anogenital condylomas. PaiTeLing is 209 widely used to treat CA to remove genital warts and to prevent recurrence.
210
The number of koilocytes reflect HPV infection. In the current study, the number of 211 koilocytes at the skin incision site as significantly higher than in the normal control and IL-12p70 in mice receiving human CA tissue were slightly higher than that in the 225 healthy control, and were significantly increased by all 4 treatment, indicating that 226 potentiation of the immune response. Specifically, TNF-α and IL-2 were the highest in 227 the imiquimod group, IFNγ was highest in the 1:2 PaiTeLing group, IL-12p70 was 228 highest in the 1:20 PaiTeLing group. IL-2 was higher in the interferon-α-2b group 229 than the 1:2 PaiTeLing group. The number of LCs was highest in the 230 imiquimod-treated group, and lowest in the interferon-α-2b group.
231
In summary, the results from the current study suggest that topical treatments with 232 imiquimod, interferon--2b and PaiTeLing could help to promote host immune 233 response to HPV. Effects seem to be strongest with imiquimod, followed by 234 PaiTeLing and then interferon-α-2b. Considering the side effects of imiquimod (e.g., 
